Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients

Oxidative stress-mediated cell damage has been considered in the pathophysiology of schizophrenia. Abnormal findings have often been considered related to differences in ethnicity, life style, dietary patterns and medications, all of which influence indices of oxidative stress and oxidative cell dam...

Full description

Saved in:
Bibliographic Details
Published inPsychiatry research Vol. 121; no. 2; pp. 109 - 122
Main Authors Ranjekar, Prabhakar K, Hinge, Ashwini, Hegde, Mahabaleshwar V, Ghate, Madhav, Kale, Anvita, Sitasawad, Sandhya, Wagh, Ulhas V, Debsikdar, Vijay B, Mahadik, Sahebarao P
Format Journal Article
LanguageEnglish
Published Shannon Elsevier Ireland Ltd 01.12.2003
Elsevier
Subjects
Online AccessGet full text
ISSN0165-1781
1872-7123
DOI10.1016/S0165-1781(03)00220-8

Cover

Abstract Oxidative stress-mediated cell damage has been considered in the pathophysiology of schizophrenia. Abnormal findings have often been considered related to differences in ethnicity, life style, dietary patterns and medications, all of which influence indices of oxidative stress and oxidative cell damage. To minimize these confounds, schizophrenic patients were compared with age-matched control subjects with the same ethnic background and similar lifestyle, as well as with bipolar mood disorder (BMD) patients. Levels of antioxidant defense enzymes (i.e. superoxide dismutase, SOD; catalase, CAT; and glutathione peroxidase, GPx) were lower in schizophrenic patients than in controls, indicating conditions for increased oxidative stress. The contents of plasma thiobarbituric acid reactive substances (TBARS) were only marginally higher in schizophrenic patients, who had normal levels of arachidonic acid (AA), a major source of TBARS, indicating no significant oxidative membrane lipid peroxidation. Levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), however, were significantly lower in schizophrenic patients. When the same indices in BMD patients were compared with findings in matched controls, levels of only SOD and CAT were lower in the patients, whereas GPx was not. Again, as in schizophrenia, the contents of TBARS were marginally higher in BMD patients with no change in levels of AA. Levels of alpha-linolenic acid and EPA were significantly lower and levels of DHA were slightly lower in BMD patients. These data indicate that certain biochemical characteristics may be common to a spectrum of psychiatric disorders, and suggest supplementation of antioxidants and essential fatty acids might affect clinical outcome.
AbstractList Oxidative stress-mediated cell damage has been considered in the pathophysiology of schizophrenia. Abnormal findings have often been considered related to differences in ethnicity, life style, dietary patterns and medications, all of which influence indices of oxidative stress and oxidative cell damage. To minimize these confounds, schizophrenic patients were compared with age-matched control subjects with the same ethnic background and similar lifestyle, as well as with bipolar mood disorder (BMD) patients. Levels of antioxidant defense enzymes (i.e. superoxide dismutase, SOD; catalase, CAT; and glutathione peroxidase, GPx) were lower in schizophrenic patients than in controls, indicating conditions for increased oxidative stress. The contents of plasma thiobarbituric acid reactive substances (TBARS) were only marginally higher in schizophrenic patients, who had normal levels of arachidonic acid (AA), a major source of TBARS, indicating no significant oxidative membrane lipid peroxidation. Levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), however, were significantly lower in schizophrenic patients. When the same indices in BMD patients were compared with findings in matched controls, levels of only SOD and CAT were lower in the patients, whereas GPx was not. Again, as in schizophrenia, the contents of TBARS were marginally higher in BMD patients with no change in levels of AA. Levels of alpha-linolenic acid and EPA were significantly lower and levels of DHA were slightly lower in BMD patients. These data indicate that certain biochemical characteristics may be common to a spectrum of psychiatric disorders, and suggest supplementation of antioxidants and essential fatty acids might affect clinical outcome.Oxidative stress-mediated cell damage has been considered in the pathophysiology of schizophrenia. Abnormal findings have often been considered related to differences in ethnicity, life style, dietary patterns and medications, all of which influence indices of oxidative stress and oxidative cell damage. To minimize these confounds, schizophrenic patients were compared with age-matched control subjects with the same ethnic background and similar lifestyle, as well as with bipolar mood disorder (BMD) patients. Levels of antioxidant defense enzymes (i.e. superoxide dismutase, SOD; catalase, CAT; and glutathione peroxidase, GPx) were lower in schizophrenic patients than in controls, indicating conditions for increased oxidative stress. The contents of plasma thiobarbituric acid reactive substances (TBARS) were only marginally higher in schizophrenic patients, who had normal levels of arachidonic acid (AA), a major source of TBARS, indicating no significant oxidative membrane lipid peroxidation. Levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), however, were significantly lower in schizophrenic patients. When the same indices in BMD patients were compared with findings in matched controls, levels of only SOD and CAT were lower in the patients, whereas GPx was not. Again, as in schizophrenia, the contents of TBARS were marginally higher in BMD patients with no change in levels of AA. Levels of alpha-linolenic acid and EPA were significantly lower and levels of DHA were slightly lower in BMD patients. These data indicate that certain biochemical characteristics may be common to a spectrum of psychiatric disorders, and suggest supplementation of antioxidants and essential fatty acids might affect clinical outcome.
Oxidative stress-mediated cell damage has been considered in the pathophysiology of schizophrenia. Abnormal findings have often been considered related to differences in ethnicity, life style, dietary patterns and medications, all of which influence indices of oxidative stress and oxidative cell damage. To minimize these confounds, schizophrenic patients were compared with age-matched control subjects with the same ethnic background and similar lifestyle, as well as with bipolar mood disorder (BMD) patients. Levels of antioxidant defense enzymes (i.e. superoxide dismutase, SOD; catalase, CAT; and glutathione peroxidase, GPx) were lower in schizophrenic patients than in controls, indicating conditions for increased oxidative stress. The contents of plasma thiobarbituric acid reactive substances (TBARS) were only marginally higher in schizophrenic patients, who had normal levels of arachidonic acid (AA), a major source of TBARS, indicating no significant oxidative membrane lipid peroxidation. Levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), however, were significantly lower in schizophrenic patients. When the same indices in BMD patients were compared with findings in matched controls, levels of only SOD and CAT were lower in the patients, whereas GPx was not. Again, as in schizophrenia, the contents of TBARS were marginally higher in BMD patients with no change in levels of AA. Levels of alpha-linolenic acid and EPA were significantly lower and levels of DHA were slightly lower in BMD patients. These data indicate that certain biochemical characteristics may be common to a spectrum of psychiatric disorders, and suggest supplementation of antioxidants and essential fatty acids might affect clinical outcome.
Author Hegde, Mahabaleshwar V
Ghate, Madhav
Debsikdar, Vijay B
Sitasawad, Sandhya
Wagh, Ulhas V
Mahadik, Sahebarao P
Hinge, Ashwini
Kale, Anvita
Ranjekar, Prabhakar K
Author_xml – sequence: 1
  givenname: Prabhakar K
  surname: Ranjekar
  fullname: Ranjekar, Prabhakar K
  organization: National Chemical Laboratory, Homi Bhabha Road, Pune 411008, India
– sequence: 2
  givenname: Ashwini
  surname: Hinge
  fullname: Hinge, Ashwini
  organization: National Chemical Laboratory, Homi Bhabha Road, Pune 411008, India
– sequence: 3
  givenname: Mahabaleshwar V
  surname: Hegde
  fullname: Hegde, Mahabaleshwar V
  organization: National Chemical Laboratory, Homi Bhabha Road, Pune 411008, India
– sequence: 4
  givenname: Madhav
  surname: Ghate
  fullname: Ghate, Madhav
  organization: MIMER Medical College, Talegaon, India
– sequence: 5
  givenname: Anvita
  surname: Kale
  fullname: Kale, Anvita
  organization: National Chemical Laboratory, Homi Bhabha Road, Pune 411008, India
– sequence: 6
  givenname: Sandhya
  surname: Sitasawad
  fullname: Sitasawad, Sandhya
  organization: National Center for Cell Science, Ganeshkhind Road, Pune 411007, India
– sequence: 7
  givenname: Ulhas V
  surname: Wagh
  fullname: Wagh, Ulhas V
  organization: Interactive Research School for Health Affairs, Bharati Vidyapeeth, Pune 411043, India
– sequence: 8
  givenname: Vijay B
  surname: Debsikdar
  fullname: Debsikdar, Vijay B
  organization: Kripamayee Research Center, Kripamayee Institute for Mental Health, Miraj, India
– sequence: 9
  givenname: Sahebarao P
  surname: Mahadik
  fullname: Mahadik, Sahebarao P
  email: mahadik@psychnts4.mcg.edu
  organization: Interactive Research School for Health Affairs, Bharati Vidyapeeth, Pune 411043, India
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15331114$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/14656446$$D View this record in MEDLINE/PubMed
BookMark eNqNkU1v1DAQhi1URLeFnwDyBQSHgO04HyuEKlQ-pUocgLM1sSeqIYm3toOanvnhTHeXIvVSfPBI9vO-o5n3iB1MYULGHkvxUgpZv_pKV1XIppXPRflCCKVE0d5jK9k2qmikKg_Y6gY5ZEcp_RBEyfX6ATuUuq5qresV-_0ObURI6DhM2YdL76hynK6WERO9OT7i2EWYkGNKSAwMfBOGZZ4S5DlCJmkPOS8crHeJ-4kne-6vwuY84uTt1qPzJIHIxxAcdz6F6DDyDWRPjukhu9_DkPDRvh6z7x_efzv9VJx9-fj59O1ZYSspc9F3yjqsQSldguirVnSVkKB006keaHBZ6lpL-tZO6BbXsrFO0oFS91VVlcfs2c53E8PFjCmb0SeLw0DThTmZRmq1blRJ4JM9OHcjOrOJfoS4mL97I-DpHoBkYehpP9anf1xVltRXE_d6x9kYUorYG-szTR2mHMEPRgpznabZpmmuozKiNNs0TUvq6pb6psEdupOdDmmZvzxGkywt2qLzEW02Lvg7Hd7ccrCDpzBh-InLf-j_AM9gy0w
CODEN PSRSDR
CitedBy_id crossref_primary_10_1016_j_jad_2013_11_008
crossref_primary_10_1080_08039488_2021_2016954
crossref_primary_10_1016_j_biopsych_2005_01_002
crossref_primary_10_1016_j_braindev_2011_01_002
crossref_primary_10_1016_j_jpsychires_2016_05_014
crossref_primary_10_1186_1471_244X_5_37
crossref_primary_10_1016_j_immbio_2012_06_003
crossref_primary_10_1016_j_neuropharm_2011_12_014
crossref_primary_10_3389_fphys_2024_1399154
crossref_primary_10_1080_1028415X_2018_1478766
crossref_primary_10_1134_S2079086414050065
crossref_primary_10_1016_j_phrs_2012_06_010
crossref_primary_10_2478_v10011_010_0018_7
crossref_primary_10_1093_schbul_sbaa062
crossref_primary_10_1016_j_pnpbp_2006_12_019
crossref_primary_10_1016_j_mhpa_2009_09_001
crossref_primary_10_1016_j_neuint_2013_02_001
crossref_primary_10_1586_ern_12_64
crossref_primary_10_1016_j_pnpbp_2005_11_034
crossref_primary_10_1517_14728222_2014_940893
crossref_primary_10_1016_j_jpsychires_2013_03_014
crossref_primary_10_1016_j_pbiomolbio_2024_11_002
crossref_primary_10_1371_journal_pone_0183812
crossref_primary_10_1186_2049_9256_1_2
crossref_primary_10_1016_j_eurpsy_2017_02_479
crossref_primary_10_1016_j_pnpbp_2013_04_020
crossref_primary_10_1017_S146114571000146X
crossref_primary_10_1093_schbul_sbv133
crossref_primary_10_1186_s12944_016_0196_5
crossref_primary_10_1111_eip_12282
crossref_primary_10_1016_j_psychres_2006_04_011
crossref_primary_10_1016_j_psychres_2018_09_009
crossref_primary_10_1016_j_biopsych_2013_03_018
crossref_primary_10_1007_s12035_015_9174_6
crossref_primary_10_1016_j_pnpbp_2008_07_001
crossref_primary_10_1016_j_pnpbp_2011_12_006
crossref_primary_10_1016_S1995_7645_10_60017_X
crossref_primary_10_1111_j_1469_7610_2010_02235_x
crossref_primary_10_1016_j_jpsychires_2008_11_005
crossref_primary_10_1016_j_pnpbp_2009_11_024
crossref_primary_10_3390_cryst10030148
crossref_primary_10_1016_j_fra_2013_03_005
crossref_primary_10_1111_pcn_12852
crossref_primary_10_1093_schbul_sbt045
crossref_primary_10_1586_14737175_2013_811981
crossref_primary_10_1016_j_pnpbp_2012_05_005
crossref_primary_10_1111_bdi_12386
crossref_primary_10_3389_fpsyt_2021_792560
crossref_primary_10_1016_j_euroneuro_2010_06_016
crossref_primary_10_1016_j_neuroscience_2016_01_067
crossref_primary_10_1080_00325481_2021_2006514
crossref_primary_10_3390_jcm11206060
crossref_primary_10_1016_j_jpsychires_2007_05_009
crossref_primary_10_1017_S1461145713001740
crossref_primary_10_4103_0019_5545_70974
crossref_primary_10_1016_j_jad_2014_10_014
crossref_primary_10_1089_act_2005_11_241
crossref_primary_10_1016_S1134_5934_09_71893_7
crossref_primary_10_1017_S1461145713000096
crossref_primary_10_1111_pcn_12163
crossref_primary_10_1177_0897190011422876
crossref_primary_10_1111_j_1399_5618_2006_00372_x
crossref_primary_10_1016_j_pnpbp_2011_08_018
crossref_primary_10_1007_s11064_006_9070_6
crossref_primary_10_1016_S1734_1140_13_71517_2
crossref_primary_10_1016_j_jpsychires_2013_06_018
crossref_primary_10_17546_msd_488247
crossref_primary_10_9758_cpn_2015_13_2_129
crossref_primary_10_1586_ern_12_98
crossref_primary_10_1080_08039488_2018_1441906
crossref_primary_10_1177_2045125319869791
crossref_primary_10_4103_0019_5545_146516
crossref_primary_10_1016_j_schres_2012_03_004
crossref_primary_10_4236_ijcm_2012_37104
crossref_primary_10_1016_j_psychres_2012_09_041
crossref_primary_10_1007_s11064_010_0195_2
crossref_primary_10_1007_s00406_007_0797_0
crossref_primary_10_1016_S0034_7450_14_60201_8
crossref_primary_10_1186_2045_9912_3_11
crossref_primary_10_1007_s11064_006_9162_3
crossref_primary_10_1016_j_psychres_2015_09_035
crossref_primary_10_1016_j_biopsych_2011_02_011
crossref_primary_10_1016_j_jpsychires_2008_01_010
crossref_primary_10_1016_j_ijmm_2013_11_018
crossref_primary_10_1186_1471_244X_12_52
crossref_primary_10_1016_j_pnpbp_2010_11_032
crossref_primary_10_1016_j_psychres_2020_113467
crossref_primary_10_1124_jpet_116_237503
crossref_primary_10_1016_j_jad_2024_03_114
crossref_primary_10_1016_j_ajp_2017_12_006
crossref_primary_10_1016_j_jad_2008_08_011
crossref_primary_10_1016_j_brainresbull_2016_10_008
crossref_primary_10_1016_j_jpsychires_2009_08_001
crossref_primary_10_1016_j_mehy_2006_07_054
crossref_primary_10_1016_j_schres_2013_11_010
crossref_primary_10_1111_j_1440_1819_2009_02015_x
crossref_primary_10_1016_j_jad_2008_04_013
crossref_primary_10_1016_j_niox_2020_11_001
crossref_primary_10_1016_j_psychres_2015_04_046
crossref_primary_10_1002_ajmg_b_31112
crossref_primary_10_1016_j_schres_2024_05_018
crossref_primary_10_4103_0019_5545_43627
crossref_primary_10_1007_s00213_016_4500_x
crossref_primary_10_1016_j_psychres_2006_03_025
crossref_primary_10_1111_j_1751_7893_2007_00021_x
crossref_primary_10_1016_j_plefa_2009_05_017
crossref_primary_10_2174_2666082218666220822154558
crossref_primary_10_1016_j_jpsychires_2012_08_010
crossref_primary_10_1177_0269881119845820
crossref_primary_10_2174_1566524023666230904150907
crossref_primary_10_1016_j_jpsychires_2006_07_013
crossref_primary_10_1016_j_schres_2012_08_014
crossref_primary_10_36290_psy_2019_014
crossref_primary_10_1016_j_jpsychires_2013_11_011
crossref_primary_10_62482_pmj_26
crossref_primary_10_1177_070674370705201202
crossref_primary_10_1016_j_bbr_2025_115528
crossref_primary_10_1016_j_pnpbp_2017_08_024
crossref_primary_10_1016_j_pnpbp_2012_10_017
crossref_primary_10_1007_s12011_014_0067_8
crossref_primary_10_1016_j_metabol_2011_02_001
crossref_primary_10_1016_j_jad_2020_05_001
crossref_primary_10_1016_j_pnpbp_2006_03_009
crossref_primary_10_1016_j_clinph_2013_05_021
crossref_primary_10_1016_j_jpsychires_2012_11_004
crossref_primary_10_1016_j_rpsm_2018_03_003
crossref_primary_10_3390_medicines9110057
crossref_primary_10_1007_s00232_010_9267_0
crossref_primary_10_1016_j_jpsychires_2014_07_028
crossref_primary_10_1017_S0954422408998620
crossref_primary_10_1021_jf073471e
crossref_primary_10_1016_j_psychres_2017_02_016
crossref_primary_10_1021_acschemneuro_2c00420
crossref_primary_10_1016_j_schres_2013_02_001
crossref_primary_10_1111_j_1399_5618_2010_00827_x
crossref_primary_10_1186_1471_244X_11_26
crossref_primary_10_3109_13651501_2015_1016973
crossref_primary_10_2217_bmm_13_83
crossref_primary_10_1016_j_schres_2015_06_022
crossref_primary_10_1016_j_jneuroim_2016_10_012
crossref_primary_10_1097_00041444_200409000_00012
crossref_primary_10_1016_j_pharmthera_2020_107520
crossref_primary_10_1016_j_psychres_2007_08_021
crossref_primary_10_4103_0019_5545_64590
crossref_primary_10_1007_s11011_009_9160_7
crossref_primary_10_1016_j_pnpbp_2017_05_005
crossref_primary_10_1016_j_psychres_2013_10_011
crossref_primary_10_1016_j_ejpsy_2020_08_001
crossref_primary_10_1016_j_neubiorev_2025_106005
crossref_primary_10_1155_2014_828702
crossref_primary_10_1097_PSY_0000000000000931
crossref_primary_10_1017_S1461145707008401
crossref_primary_10_2165_11539700_000000000_00000
crossref_primary_10_1016_j_ibneur_2023_11_007
crossref_primary_10_1016_j_jprot_2016_04_034
crossref_primary_10_3390_antiox9080714
crossref_primary_10_1586_ern_09_31
crossref_primary_10_1186_s12888_014_0268_x
crossref_primary_10_1016_j_pharep_2014_12_015
crossref_primary_10_1016_j_pnpbp_2006_06_011
crossref_primary_10_1016_j_psychres_2013_05_006
crossref_primary_10_1007_s00213_013_3397_x
crossref_primary_10_1002_ajhb_21129
crossref_primary_10_3389_fcell_2021_615569
crossref_primary_10_1016_j_enzmictec_2005_08_040
crossref_primary_10_1124_pr_107_00107
crossref_primary_10_1016_j_plefa_2010_07_001
crossref_primary_10_3390_antiox11101870
crossref_primary_10_1007_s11033_020_05354_1
crossref_primary_10_3390_brainsci14121199
crossref_primary_10_1016_j_pnpbp_2006_09_012
crossref_primary_10_1016_j_schres_2005_05_019
crossref_primary_10_1016_j_schres_2007_09_036
crossref_primary_10_30773_pi_2016_12_31
crossref_primary_10_1016_j_pnpbp_2012_07_013
crossref_primary_10_1007_s10528_024_10986_0
crossref_primary_10_1007_s12264_022_00871_4
crossref_primary_10_1089_ars_2010_3508
crossref_primary_10_1016_j_ijdevneu_2010_02_002
crossref_primary_10_1111_j_1601_183X_2011_00712_x
crossref_primary_10_1002_jnr_20875
crossref_primary_10_1016_j_jtemb_2024_127532
crossref_primary_10_1016_j_pnpbp_2013_02_015
crossref_primary_10_1002_hup_2453
crossref_primary_10_1016_j_pnpbp_2013_02_007
crossref_primary_10_1177_0004563214528882
crossref_primary_10_1016_j_neuint_2020_104877
crossref_primary_10_1016_j_pnpbp_2007_08_003
crossref_primary_10_1016_j_mehy_2011_03_051
crossref_primary_10_1016_j_tins_2008_07_007
crossref_primary_10_1016_j_phanu_2012_10_004
crossref_primary_10_1016_j_mehy_2020_110433
crossref_primary_10_1586_ern_11_42
crossref_primary_10_1016_j_neulet_2009_12_072
crossref_primary_10_1186_s12991_021_00354_2
crossref_primary_10_1016_j_psc_2015_10_003
crossref_primary_10_1007_s11011_018_0209_3
crossref_primary_10_1007_s12640_016_9621_9
crossref_primary_10_3389_fdmed_2025_1542913
crossref_primary_10_1016_j_plefa_2006_07_009
crossref_primary_10_1016_j_plefa_2006_07_008
crossref_primary_10_2174_1381612826666201113095938
crossref_primary_10_1002_hup_2272
crossref_primary_10_1177_0269881117731169
crossref_primary_10_4236_ojpsych_2011_11001
crossref_primary_10_1016_j_jpsychires_2011_10_004
crossref_primary_10_1016_j_neubiorev_2010_10_008
crossref_primary_10_1016_j_plefa_2006_07_010
crossref_primary_10_1016_j_schres_2005_10_011
crossref_primary_10_1155_2024_9979582
crossref_primary_10_1007_s12031_018_1165_4
crossref_primary_10_1002_jnr_20570
crossref_primary_10_1093_ajcn_85_6_1665
crossref_primary_10_9758_cpn_23_1084
crossref_primary_10_1016_j_bpsgos_2023_07_004
crossref_primary_10_3109_00365513_2013_873947
crossref_primary_10_1038_sj_mp_4001888
crossref_primary_10_1016_j_psychres_2008_10_038
crossref_primary_10_1111_j_1440_1819_2010_02178_x
crossref_primary_10_1515_cclm_2015_0212
crossref_primary_10_3390_medicina58101491
crossref_primary_10_1002_ajmg_b_30791
crossref_primary_10_1016_j_plefa_2008_11_004
crossref_primary_10_1016_j_ncl_2015_08_011
crossref_primary_10_3892_br_2018_1040
crossref_primary_10_1016_j_jpsychires_2006_04_006
crossref_primary_10_1038_sj_npp_1301628
crossref_primary_10_1017_S1461145709990654
crossref_primary_10_3389_fpsyt_2021_546801
crossref_primary_10_1016_j_ejphar_2006_03_076
crossref_primary_10_1016_j_neubiorev_2017_08_025
crossref_primary_10_1007_s40263_016_0343_6
crossref_primary_10_1177_0884533611411306
crossref_primary_10_1007_s12035_018_1051_7
crossref_primary_10_1016_j_pnpbp_2007_03_008
crossref_primary_10_1016_j_psyneuen_2014_09_029
crossref_primary_10_1002_prca_200700230
crossref_primary_10_1016_j_psychres_2014_04_005
crossref_primary_10_3109_15622975_2010_526146
crossref_primary_10_1016_j_psychres_2009_01_017
crossref_primary_10_1016_j_jpsychires_2006_11_004
crossref_primary_10_1111_j_1399_5618_2007_00387_x
crossref_primary_10_1016_j_psychres_2009_01_013
crossref_primary_10_1016_j_pnpbp_2012_06_013
crossref_primary_10_1007_s12011_020_02346_x
crossref_primary_10_1080_01480545_2023_2219039
crossref_primary_10_3389_fnut_2019_00076
crossref_primary_10_1016_j_jad_2007_11_002
crossref_primary_10_1177_0960327113493305
crossref_primary_10_1016_j_immbio_2012_10_005
crossref_primary_10_1016_j_pnpbp_2017_01_007
crossref_primary_10_1016_j_neulet_2006_08_026
crossref_primary_10_1186_1471_244X_11_124
crossref_primary_10_3390_brainsci11070917
crossref_primary_10_4103_0019_5545_39753
crossref_primary_10_1080_15622970801901802
crossref_primary_10_1016_j_neulet_2007_05_016
crossref_primary_10_1016_j_neubiorev_2007_10_005
crossref_primary_10_1016_j_rpsmen_2018_03_001
crossref_primary_10_1002_dneu_22329
crossref_primary_10_1016_j_psychres_2010_07_049
crossref_primary_10_1002_biof_1093
crossref_primary_10_1016_j_neulet_2016_02_031
crossref_primary_10_1002_ajmg_b_30776
crossref_primary_10_1515_cclm_2013_0978
crossref_primary_10_1016_j_plefa_2006_02_001
crossref_primary_10_1016_j_pnpbp_2009_06_018
crossref_primary_10_1016_j_psychres_2006_05_025
crossref_primary_10_1016_j_pnpbp_2006_12_020
crossref_primary_10_1002_hbm_21438
crossref_primary_10_1016_j_biopsych_2005_04_052
crossref_primary_10_1016_j_plefa_2007_10_006
crossref_primary_10_1080_09540260600581993
Cites_doi 10.1016/S0920-9964(97)00005-4
10.1016/S0920-9964(01)00334-6
10.1017/S0264180100000904
10.2466/pr0.1962.10.3.799
10.1176/ajp.150.9.1405
10.1001/archpsyc.56.5.407
10.1016/0003-2697(79)90738-3
10.1001/archpsyc.1988.01800320058007
10.1016/S0022-3956(02)00048-1
10.1016/S0022-3956(01)00048-6
10.1016/0165-1781(96)02899-5
10.1093/clinchem/32.5.805
10.1016/S0165-1781(99)00014-1
10.1176/ajp.149.1.22
10.1093/ajcn/54.3.438
10.1016/S0149-7634(05)80180-0
10.1176/appi.ajp.159.3.477
10.1111/j.1471-4159.1984.tb02728.x
10.1016/0006-291X(91)91228-5
10.1017/S0033291700032797
10.1093/schbul/11.3.471
10.1093/schbul/12.1.52
10.1016/S0920-9964(97)00151-5
10.1016/0920-9964(94)90084-1
10.1016/0006-3223(91)90298-Z
10.2165/00023210-200115040-00004
10.1002/cbf.940
10.1016/S0278-5846(02)00220-8
10.1016/S0920-9964(99)00095-X
10.1016/S0006-3223(99)00092-X
10.1111/j.1600-0447.1988.tb06388.x
10.1016/S0006-3223(02)01443-9
10.1016/S0920-9964(02)00284-0
10.1016/S0952-3278(96)90147-7
10.1001/archpsyc.1982.04290070025006
10.1016/0920-9964(94)90043-4
10.1176/ajp.145.5.578
10.1016/j.plefa.2003.08.010
10.1192/bjp.156.6.788
10.1016/0920-9964(95)00048-8
10.1001/archpsyc.1988.01800280038006
10.1016/S0278-5846(00)00181-0
10.1016/0006-2952(94)00424-K
10.1016/S0952-3278(96)90142-8
10.1176/appi.ajp.158.9.1449
10.1016/S0022-3956(98)00028-4
10.1001/archpsyc.1993.01820230041004
10.1016/S0952-3278(96)90143-X
10.1016/0006-3223(90)90461-A
10.1093/schbul/14.2.291
10.1016/0920-9964(95)00049-6
10.1016/S0920-9964(02)00328-6
10.1016/0165-1781(93)90054-K
10.1016/S0952-3278(96)90144-1
10.1016/0006-3223(90)90490-S
10.1016/S0006-3223(97)00282-5
10.1097/00004850-199300830-00003
10.1093/schbul/13.2.261
ContentType Journal Article
Copyright 2003 Elsevier Ireland Ltd
2004 INIST-CNRS
Copyright_xml – notice: 2003 Elsevier Ireland Ltd
– notice: 2004 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/S0165-1781(03)00220-8
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1872-7123
EndPage 122
ExternalDocumentID 14656446
15331114
10_1016_S0165_1781_03_00220_8
S0165178103002208
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.GJ
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
29P
4.4
457
4G.
53G
5VS
7-5
71M
8P~
9JM
9JO
AABNK
AADFP
AAEDT
AAEDW
AAGJA
AAGKA
AAGUQ
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXLA
AAXUO
AAYWO
ABBQC
ABCQJ
ABFNM
ABIVO
ABJNI
ABMAC
ABMZM
ABOYX
ABWVN
ABXDB
ACDAQ
ACGFS
ACHQT
ACIEU
ACIUM
ACRLP
ACRPL
ACVFH
ACXNI
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADVLN
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEG
HMK
HMO
HMQ
HMW
HVGLF
HZ~
IHE
J1W
KOM
M29
M2V
M39
M3V
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OH0
OKEIE
OU-
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SNS
SPCBC
SPS
SSB
SSH
SSN
SSY
SSZ
T5K
UV1
WUQ
Z5R
ZGI
~G-
AACTN
AADPK
AAIAV
ABLVK
ABYKQ
AFCTW
AFKWA
AFYLN
AJBFU
AJOXV
AMFUW
EFLBG
LCYCR
RIG
ZA5
AAYXX
ACLOT
CITATION
~HD
AAPBV
ABPIF
ABPTK
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c511t-fb2cde6a2243a0f580b501a247b2fa1871346412244d048e917cd1111a34f5553
IEDL.DBID .~1
ISSN 0165-1781
IngestDate Sat Sep 27 17:42:58 EDT 2025
Wed Feb 19 02:33:24 EST 2025
Sun Oct 22 16:05:42 EDT 2023
Thu Apr 24 23:11:05 EDT 2025
Wed Oct 01 04:10:04 EDT 2025
Fri Feb 23 02:26:41 EST 2024
Tue Aug 26 16:35:33 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Schizophrenia
Bipolar mood disorder
Essential fatty acids
Antioxidant enzymes
Lipid peroxides
Mood disorder
Glutathione peroxidase
Human
Oxidative stress
Biochemical analysis
Pathophysiology
Enzyme
Polyunsaturated fatty acid
Biological marker
Lipids
Superoxide dismutase
Bipolar disorder
Antioxidant
n-3 fatty acid
Psychosis
Blood concentration
n-6 fatty acid
Peroxidases
Catalase
Unsaturated fatty acid
Oxidoreductases
Comparative study
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c511t-fb2cde6a2243a0f580b501a247b2fa1871346412244d048e917cd1111a34f5553
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 14656446
PQID 71429723
PQPubID 23479
PageCount 14
ParticipantIDs proquest_miscellaneous_71429723
pubmed_primary_14656446
pascalfrancis_primary_15331114
crossref_citationtrail_10_1016_S0165_1781_03_00220_8
crossref_primary_10_1016_S0165_1781_03_00220_8
elsevier_sciencedirect_doi_10_1016_S0165_1781_03_00220_8
elsevier_clinicalkey_doi_10_1016_S0165_1781_03_00220_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2003-12-01
PublicationDateYYYYMMDD 2003-12-01
PublicationDate_xml – month: 12
  year: 2003
  text: 2003-12-01
  day: 01
PublicationDecade 2000
PublicationPlace Shannon
PublicationPlace_xml – name: Shannon
– name: Ireland
PublicationTitle Psychiatry research
PublicationTitleAlternate Psychiatry Res
PublicationYear 2003
Publisher Elsevier Ireland Ltd
Elsevier
Publisher_xml – name: Elsevier Ireland Ltd
– name: Elsevier
References McCreadie, MacDonald, Wiles, Campbell, Pateson (BIB51) 1995; 170
Evans, D.R., Parikh, V.V., Khan, M.M., Coussons, C., Buckley, P.F., Mahadik, S.P., 2003. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids, in press
Lohr, Cadet, Lohr, Larson, Wasli, Wade, Hylton, Vidoni, Jeste, Wyatt (BIB37) 1988; 14
Glen, Glen, Horrobin, Vaddadi, Spellman, Morse-Fischer, Ellis, Skinner (BIB22) 1994; 12
Crow (BIB15) 1985; 11
Wainwright (BIB70) 1992; 16
Adler, Peselow, Rotrosen, Duncan, Lee, Rosenthal, Angrist (BIB2) 1993; 150
Peet, Horrobin (BIB57) 2002; 36
(BIB5) 1994
Fenton, Hibbeln, Knable (BIB20) 2000; 47
Subramanyam, Pond, Eyles, Whiteford, Founda, Castagnoli (BIB68) 1991; 181
Arvindakshan, Sitasawad, Debsikdar, Ghate, Horrobin, Bennett, Ranjekar, Mahadik (BIB10) 2003; 53
Kahlbaum, K., 1963. Die Gruppirung der Psychischen Krankheiten und die Eintheilung der Seelenstorungen. AW Kafemann, Danzing
Andreasen, Olsen (BIB6) 1982; 39
Jablensky, Häfner (BIB26) 1986; 40
Mahadik, Mukherjee, Correnti, Scheffer, Mahadik (BIB47) 1998; 43
Mahadik, Mukherjee (BIB43) 1996; 19
Khan, Khan, Leventhal, Brown (BIB31) 2001; 158
Arvindakshan, M., 2003. Ph.D. Thesis: The Role of Membrane Essential Polyunsaturated Fatty Acids in Schizophrenia Outcome. Pune University Press, Pune, India
Parikh, Khan, Mahadik (BIB56) 2002; 37
Roy, Pathak, Singh (BIB63) 1984; 42
Ramchand, Davies, Tresman, Griffiths, Peet (BIB60) 1996; 55
Khan, Evans, Gunna, Scheffer, Parikh, Mahadik (BIB32) 2002; 58
Aebi (BIB3) 1984; 3
Stoklasova, Petrakova, Michalickova, Zapletalek (BIB66) 1990; 33
Kirkpatrick, Buchanan, Breier, Carpenter (BIB33) 1993; 47
Mahadik, Mukherjee, Horrobin, Jenkins, Correnti, Scheffer (BIB45) 1996; 63
Mukherjee, Mahadik, Scheffer, Correnti, Kelkar (BIB52) 1996; 19
Christensen, Christensen (BIB14) 1988; 78
Cadet, Perumal (BIB12) 1990; 28
Peet, Laugharne, Rangarajan, Reynolds (BIB59) 1993; 8
Akyol, Herken, Uz, Fadillioglu, Unal, Sogut, Ozyurt, Savas (BIB4) 2002; 26
Jablensky, Sartorius, Ernberg, Anker, Korten, Cooper, Day, Bertelsen (BIB27) 1991; 20
Gershon, DeLisi, Hamovit, Nurnberg, Maxwell, Schreiber, Dauphinais, Dingman, Guroff (BIB21) 1988; 45
Mahadik, Evans (BIB40) 1997; 33
Maier, Lichtermann, Minges, Hallmayer, Heun, Benkert, Levinson (BIB50) 1993; 50
Simopoulos (BIB64) 1991; 54
Kraepelin, E., 1899. Psychiatrie. Ein Lehrbuch fur Studierende und Arzte, 6th ed. Johann Ambrocius Barth, Leipzig
Maes, Chritophe, Delanghe, Altamura, Neels, Meltzer (BIB39) 1999; 85
Nemets, Stahl, Belmaker (BIB53) 2002; 159
Williams (BIB71) 1988; 45
Crow (BIB17) 1995
Edwards, R.W., Peet, M., 1999. Essential fatty acid intake in relation to depression. In: Peet, M., Glen, I., Horrobin, D.F. (Eds.), Phospholipid Spectrum Disorders in Psychiatry. Marius Press, Lancashire, UK
Overall, Gorham (BIB55) 1962; 10
Yao, Reddy, van Kammen (BIB74) 2001; 15
Reddy, Mahadik, Mukherjee, Murthy (BIB61) 1991; 30
Mahadik, Mulchandani, Hegde, Ranjekar (BIB48) 1999
Mahadik, Scheffer (BIB44) 1996; 55
Smythies (BIB65) 1997; 24
Yao, Leonard, Reddy (BIB73) 2000; 42
Abdalla, Monteiro, Oliveira, Bechara (BIB1) 1986; 32
Horrobin, Glen, Vaddadi (BIB23) 1994; 13
Kuloglu, Ustundag, Atmaca, Canatan, Tezcan, Clinkilinc (BIB35) 2002; 20
Ohkawa, Ohishi, Yagi (BIB54) 1979; 95
Carpenter, Heinrichs, Wagman (BIB13) 1988; 145
Yao, Reddy, McElhinny, van Kammen (BIB72) 1998; 32
Mahadik, Evans, Lal (BIB41) 2001; 25
Jeding, Evans, Akanmu, Dexter, Spencer, Aruoma, Jenner, Halliwell (BIB28) 1995; 49
Crow (BIB16) 1990; 156
Mahadik, Sitasawad, Mulchandani (BIB49) 1999
Kay, Fiszbein, Opler (BIB30) 1987; 13
Mahadik, Shendarkar, Scheffer, Mukherjee, Correnti (BIB46) 1996; 55
Cadet, Lohr (BIB11) 1987; 5
Stoll, Severus, Freeman, Rueter, Zboyan, Diamond, Cress, Marangell (BIB67) 1999; 56
Horrobin (BIB24) 1998; 30
Lohr, Underhill, Moir, Jeste (BIB38) 1990; 28
Angst (BIB7) 2002; 57
Reddy, Yao (BIB62) 1996; 55
Leff, Sartorius, Jablensky, Korten, Ernberg (BIB36) 1992; 22
Peet, M., Glen, I., Horrobin, D.F. (Eds), 1999. Phospholipid Spectrum Disorders in Psychiatry. Marius Press Lancashire, UK
Arvindakshan, Ghate, Ranjekar, Evans, Mahadik (BIB9) 2003; 62
Jablensky (BIB25) 1986; 12
Mahadik, Gowda (BIB42) 1996; 32
Taylor (BIB69) 1992; 149
Kirkpatrick (10.1016/S0165-1781(03)00220-8_BIB33) 1993; 47
10.1016/S0165-1781(03)00220-8_BIB58
Cadet (10.1016/S0165-1781(03)00220-8_BIB11) 1987; 5
Mahadik (10.1016/S0165-1781(03)00220-8_BIB46) 1996; 55
Peet (10.1016/S0165-1781(03)00220-8_BIB57) 2002; 36
10.1016/S0165-1781(03)00220-8_BIB19
10.1016/S0165-1781(03)00220-8_BIB18
Taylor (10.1016/S0165-1781(03)00220-8_BIB69) 1992; 149
Jablensky (10.1016/S0165-1781(03)00220-8_BIB26) 1986; 40
Aebi (10.1016/S0165-1781(03)00220-8_BIB3) 1984; 3
McCreadie (10.1016/S0165-1781(03)00220-8_BIB51) 1995; 170
Reddy (10.1016/S0165-1781(03)00220-8_BIB61) 1991; 30
Khan (10.1016/S0165-1781(03)00220-8_BIB31) 2001; 158
Mukherjee (10.1016/S0165-1781(03)00220-8_BIB52) 1996; 19
Ohkawa (10.1016/S0165-1781(03)00220-8_BIB54) 1979; 95
Andreasen (10.1016/S0165-1781(03)00220-8_BIB6) 1982; 39
Mahadik (10.1016/S0165-1781(03)00220-8_BIB43) 1996; 19
Yao (10.1016/S0165-1781(03)00220-8_BIB74) 2001; 15
Lohr (10.1016/S0165-1781(03)00220-8_BIB37) 1988; 14
Khan (10.1016/S0165-1781(03)00220-8_BIB32) 2002; 58
Parikh (10.1016/S0165-1781(03)00220-8_BIB56) 2002; 37
Yao (10.1016/S0165-1781(03)00220-8_BIB72) 1998; 32
Stoklasova (10.1016/S0165-1781(03)00220-8_BIB66) 1990; 33
Adler (10.1016/S0165-1781(03)00220-8_BIB2) 1993; 150
Fenton (10.1016/S0165-1781(03)00220-8_BIB20) 2000; 47
Christensen (10.1016/S0165-1781(03)00220-8_BIB14) 1988; 78
Mahadik (10.1016/S0165-1781(03)00220-8_BIB41) 2001; 25
Peet (10.1016/S0165-1781(03)00220-8_BIB59) 1993; 8
Mahadik (10.1016/S0165-1781(03)00220-8_BIB40) 1997; 33
Crow (10.1016/S0165-1781(03)00220-8_BIB17) 1995
Kuloglu (10.1016/S0165-1781(03)00220-8_BIB35) 2002; 20
Kay (10.1016/S0165-1781(03)00220-8_BIB30) 1987; 13
Maes (10.1016/S0165-1781(03)00220-8_BIB39) 1999; 85
Mahadik (10.1016/S0165-1781(03)00220-8_BIB45) 1996; 63
10.1016/S0165-1781(03)00220-8_BIB34
Simopoulos (10.1016/S0165-1781(03)00220-8_BIB64) 1991; 54
Mahadik (10.1016/S0165-1781(03)00220-8_BIB48) 1999
Cadet (10.1016/S0165-1781(03)00220-8_BIB12) 1990; 28
Arvindakshan (10.1016/S0165-1781(03)00220-8_BIB10) 2003; 53
Abdalla (10.1016/S0165-1781(03)00220-8_BIB1) 1986; 32
Carpenter (10.1016/S0165-1781(03)00220-8_BIB13) 1988; 145
Maier (10.1016/S0165-1781(03)00220-8_BIB50) 1993; 50
Horrobin (10.1016/S0165-1781(03)00220-8_BIB24) 1998; 30
Jablensky (10.1016/S0165-1781(03)00220-8_BIB27) 1991; 20
Crow (10.1016/S0165-1781(03)00220-8_BIB16) 1990; 156
Reddy (10.1016/S0165-1781(03)00220-8_BIB62) 1996; 55
Overall (10.1016/S0165-1781(03)00220-8_BIB55) 1962; 10
Akyol (10.1016/S0165-1781(03)00220-8_BIB4) 2002; 26
Roy (10.1016/S0165-1781(03)00220-8_BIB63) 1984; 42
Wainwright (10.1016/S0165-1781(03)00220-8_BIB70) 1992; 16
Jablensky (10.1016/S0165-1781(03)00220-8_BIB25) 1986; 12
Nemets (10.1016/S0165-1781(03)00220-8_BIB53) 2002; 159
Arvindakshan (10.1016/S0165-1781(03)00220-8_BIB9) 2003; 62
Stoll (10.1016/S0165-1781(03)00220-8_BIB67) 1999; 56
Leff (10.1016/S0165-1781(03)00220-8_BIB36) 1992; 22
10.1016/S0165-1781(03)00220-8_BIB8
Subramanyam (10.1016/S0165-1781(03)00220-8_BIB68) 1991; 181
Gershon (10.1016/S0165-1781(03)00220-8_BIB21) 1988; 45
Horrobin (10.1016/S0165-1781(03)00220-8_BIB23) 1994; 13
Mahadik (10.1016/S0165-1781(03)00220-8_BIB47) 1998; 43
10.1016/S0165-1781(03)00220-8_BIB29
Mahadik (10.1016/S0165-1781(03)00220-8_BIB49) 1999
Ramchand (10.1016/S0165-1781(03)00220-8_BIB60) 1996; 55
Mahadik (10.1016/S0165-1781(03)00220-8_BIB42) 1996; 32
Lohr (10.1016/S0165-1781(03)00220-8_BIB38) 1990; 28
Smythies (10.1016/S0165-1781(03)00220-8_BIB65) 1997; 24
Mahadik (10.1016/S0165-1781(03)00220-8_BIB44) 1996; 55
Yao (10.1016/S0165-1781(03)00220-8_BIB73) 2000; 42
Jeding (10.1016/S0165-1781(03)00220-8_BIB28) 1995; 49
Williams (10.1016/S0165-1781(03)00220-8_BIB71) 1988; 45
(10.1016/S0165-1781(03)00220-8_BIB5) 1994
Crow (10.1016/S0165-1781(03)00220-8_BIB15) 1985; 11
Glen (10.1016/S0165-1781(03)00220-8_BIB22) 1994; 12
Angst (10.1016/S0165-1781(03)00220-8_BIB7) 2002; 57
References_xml – volume: 43
  start-page: 674
  year: 1998
  end-page: 679
  ident: BIB47
  article-title: Elevated plasma lipid peroxides at the onset of non-affective psychosis
  publication-title: Biological Psychiatry
– reference: Peet, M., Glen, I., Horrobin, D.F. (Eds), 1999. Phospholipid Spectrum Disorders in Psychiatry. Marius Press Lancashire, UK
– volume: 62
  start-page: 195
  year: 2003
  end-page: 204
  ident: BIB9
  article-title: Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia
  publication-title: Schizophrenia Research
– volume: 45
  start-page: 742
  year: 1988
  end-page: 747
  ident: BIB71
  article-title: A structured interview guide for the Hamilton Depression Rating Scale
  publication-title: Archives of General Psychiatry
– volume: 145
  start-page: 578
  year: 1988
  end-page: 583
  ident: BIB13
  article-title: Deficit and non-deficit forms of schizophrenia: the concept
  publication-title: American Journal of Psychiatry
– volume: 39
  start-page: 789
  year: 1982
  end-page: 794
  ident: BIB6
  article-title: Negative vs. positive schizophrenia: definition and validation
  publication-title: Archives of General Psychiatry
– volume: 56
  start-page: 407
  year: 1999
  end-page: 412
  ident: BIB67
  article-title: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial
  publication-title: Archives of General Psychiatry
– volume: 19
  start-page: 19
  year: 1996
  end-page: 26
  ident: BIB52
  article-title: Impaired antioxidant defense at the onset of psychosis
  publication-title: Schizophrenia Research
– volume: 20
  start-page: 1
  year: 1991
  end-page: 97
  ident: BIB27
  article-title: Schizophrenia: manifestations, incidence and course in different cultures
  publication-title: Psychological Medicine and Monographs Supplement
– volume: 28
  start-page: 535
  year: 1990
  end-page: 539
  ident: BIB38
  article-title: Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia
  publication-title: Biological Psychiatry
– volume: 78
  start-page: 587
  year: 1988
  end-page: 591
  ident: BIB14
  article-title: Fat consumption and schizophrenia
  publication-title: Acta Psychiatrica Scandinavica
– volume: 156
  start-page: 788
  year: 1990
  end-page: 797
  ident: BIB16
  article-title: The continuum of psychosis and its genetic origins: the sixty-fifth Maudsley Lecture
  publication-title: British Journal of Psychiatry
– volume: 159
  start-page: 477
  year: 2002
  end-page: 479
  ident: BIB53
  article-title: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder
  publication-title: American Journal of Psychiatry
– start-page: 167
  year: 1999
  end-page: 179
  ident: BIB48
  article-title: Cultural and socio–economic differences in dietary intake of essential fatty acids and antioxidants: effects on the course and outcome of schizophrenia
  publication-title: Phospholipid Spectrum Disorders in Psychiatry
– volume: 16
  start-page: 193
  year: 1992
  end-page: 205
  ident: BIB70
  article-title: Do essential fatty acids play a role in brain and behavioral development?
  publication-title: Neuroscience and Biobehavioral Reviews
– volume: 33
  start-page: 5
  year: 1997
  end-page: 17
  ident: BIB40
  article-title: Essential fatty acids in the treatment of schizophrenia
  publication-title: Drugs of Today
– volume: 37
  start-page: 43
  year: 2002
  end-page: 51
  ident: BIB56
  article-title: Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain
  publication-title: Journal of Psychiatric Research
– volume: 13
  start-page: 195
  year: 1994
  end-page: 207
  ident: BIB23
  article-title: The membrane hypothesis of schizophrenia
  publication-title: Schizophrenia Research
– reference: Edwards, R.W., Peet, M., 1999. Essential fatty acid intake in relation to depression. In: Peet, M., Glen, I., Horrobin, D.F. (Eds.), Phospholipid Spectrum Disorders in Psychiatry. Marius Press, Lancashire, UK
– volume: 11
  start-page: 471
  year: 1985
  end-page: 486
  ident: BIB15
  article-title: The two-syndrome concept: origins and current status
  publication-title: Schizophrenia Bulletin
– volume: 95
  start-page: 351
  year: 1979
  end-page: 358
  ident: BIB54
  article-title: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction
  publication-title: Analytical Biochemistry
– volume: 49
  start-page: 359
  year: 1995
  end-page: 365
  ident: BIB28
  article-title: Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs
  publication-title: Biochemical Pharmacology
– volume: 57
  start-page: 5
  year: 2002
  end-page: 13
  ident: BIB7
  article-title: Historical aspects of the dichotomy between manic-depressive disorders and schizophrenia
  publication-title: Schizophrenia Research
– reference: Evans, D.R., Parikh, V.V., Khan, M.M., Coussons, C., Buckley, P.F., Mahadik, S.P., 2003. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids, in press
– volume: 22
  start-page: 131
  year: 1992
  end-page: 145
  ident: BIB36
  article-title: The International Pilot Study of Schizophrenia: five-year follow-up findings
  publication-title: Psychological Medicine
– volume: 42
  start-page: 628
  year: 1984
  end-page: 633
  ident: BIB63
  article-title: Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidation in the various regions of aging rat brain
  publication-title: Journal of Neurochemistry
– volume: 12
  start-page: 53
  year: 1994
  end-page: 61
  ident: BIB22
  article-title: A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases
  publication-title: Schizophrenia Research
– volume: 20
  start-page: 171
  year: 2002
  end-page: 175
  ident: BIB35
  article-title: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder
  publication-title: Cell Biochemistry and Function
– start-page: 99
  year: 1999
  end-page: 111
  ident: BIB49
  article-title: Membrane peroxidation and the neuropathology of schizophrenia
  publication-title: Phospholipid Spectrum Disorders in Psychiatry
– volume: 25
  start-page: 463
  year: 2001
  end-page: 493
  ident: BIB41
  article-title: Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia
  publication-title: Progress in Neuropsychopharmacology and Biological Psychiatry
– volume: 45
  start-page: 328
  year: 1988
  end-page: 336
  ident: BIB21
  article-title: A controlled family study of chronic psychosis
  publication-title: Archives of General Psychiatry
– reference: Kraepelin, E., 1899. Psychiatrie. Ein Lehrbuch fur Studierende und Arzte, 6th ed. Johann Ambrocius Barth, Leipzig
– volume: 181
  start-page: 573
  year: 1991
  end-page: 578
  ident: BIB68
  article-title: Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol
  publication-title: Biochemical and Biophysical Research Communications
– volume: 13
  start-page: 261
  year: 1987
  end-page: 276
  ident: BIB30
  article-title: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
  publication-title: Schizophrenia Bulletin
– volume: 32
  start-page: 385
  year: 1998
  end-page: 391
  ident: BIB72
  article-title: Effects of haloperidol on antioxidant defense system enzymes in schizophrenia
  publication-title: Journal of Psychiatric Research
– volume: 54
  start-page: 438
  year: 1991
  end-page: 463
  ident: BIB64
  article-title: Omega-3 fatty acids in health and disease and in growth and development
  publication-title: American Journal of Clinical Nutrition
– volume: 24
  start-page: 357
  year: 1997
  end-page: 364
  ident: BIB65
  article-title: Oxidative reactions and schizophrenia: a review-discussion
  publication-title: Schizophrenia Research
– volume: 53
  start-page: 56
  year: 2003
  end-page: 64
  ident: BIB10
  article-title: Membrane essential polyunsaturated fatty acids (EPUFA) and schizophrenia outcome: EPUFA and lipid peroxide levels in never-medicated and medicated schizophrenics
  publication-title: Biological Psychiatry
– volume: 85
  start-page: 275
  year: 1999
  end-page: 291
  ident: BIB39
  article-title: Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients
  publication-title: Psychiatric Research
– reference: Kahlbaum, K., 1963. Die Gruppirung der Psychischen Krankheiten und die Eintheilung der Seelenstorungen. AW Kafemann, Danzing
– volume: 149
  start-page: 22
  year: 1992
  end-page: 32
  ident: BIB69
  article-title: Are schizophrenia and affective disorder related? A selective literature review
  publication-title: American Journal of Psychiatry
– volume: 55
  start-page: 33
  year: 1996
  end-page: 43
  ident: BIB62
  article-title: Free radical pathology in schizophrenia: a review
  publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids
– volume: 14
  start-page: 291
  year: 1988
  end-page: 296
  ident: BIB37
  article-title: Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms
  publication-title: Schizophrenia Bulletin
– volume: 32
  start-page: 553
  year: 1996
  end-page: 565
  ident: BIB42
  article-title: Antioxidants in the treatment of schizophrenia
  publication-title: Drugs of Today
– volume: 30
  start-page: 193
  year: 1998
  end-page: 208
  ident: BIB24
  article-title: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia
  publication-title: Schizophrenia Research
– volume: 55
  start-page: 65
  year: 1996
  end-page: 70
  ident: BIB46
  article-title: Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls
  publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids
– volume: 40
  start-page: 1
  year: 1986
  end-page: 163
  ident: BIB26
  article-title: Schizophrenia and social adjustment. A prospective longitudinal study
  publication-title: Monogr Gesamtgeb Psychiatr Psychiatry Series
– volume: 170
  start-page: 1
  year: 1995
  end-page: 8
  ident: BIB51
  article-title: The Nithsdale Schizophrenia Surveys XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia and in normal subjects
  publication-title: British Journal of Psychiatry
– volume: 3
  start-page: 277
  year: 1984
  end-page: 281
  ident: BIB3
  article-title: Catalase in vitro
  publication-title: Methods of Enzymatic Analysis
– volume: 28
  start-page: 738
  year: 1990
  end-page: 740
  ident: BIB12
  article-title: Chronic treatment with prolixin causes oxidative stress in rat brain
  publication-title: Biological Psychiatry
– start-page: 151
  year: 1995
  end-page: 163
  ident: BIB17
  article-title: Psychotic continuum or disease entities? The critical impact of nosology on the problem of etiology
  publication-title: Psychotic Continuum
– volume: 19
  start-page: 1
  year: 1996
  end-page: 17
  ident: BIB43
  article-title: Free radical pathology and antioxidant defense in schizophrenia: a review
  publication-title: Schizophrenia Research
– volume: 47
  start-page: 47
  year: 1993
  end-page: 56
  ident: BIB33
  article-title: Case identification and stability of the deficit syndrome of schizophrenia
  publication-title: Psychiatry Research
– volume: 55
  start-page: 45
  year: 1996
  end-page: 54
  ident: BIB44
  article-title: Oxidative injury and potential use of antioxidants in schizophrenia
  publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids
– volume: 158
  start-page: 1449
  year: 2001
  end-page: 1454
  ident: BIB31
  article-title: Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database
  publication-title: American Journal of Psychiatry
– volume: 55
  start-page: 27
  year: 1996
  end-page: 31
  ident: BIB60
  article-title: Reduced susceptibility to oxidative damage of erythrocyte membranes from medicated schizophrenic patients
  publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids
– volume: 12
  start-page: 52
  year: 1986
  end-page: 73
  ident: BIB25
  article-title: Epidemiology of schizophrenia: a European perspective
  publication-title: Schizophrenia Bulletin
– volume: 58
  start-page: 1
  year: 2002
  end-page: 10
  ident: BIB32
  article-title: Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics
  publication-title: Schizophrenia Research
– volume: 10
  start-page: 799
  year: 1962
  end-page: 812
  ident: BIB55
  article-title: Brief Psychiatric Rating Scale
  publication-title: Psychological Reports
– volume: 36
  start-page: 7
  year: 2002
  end-page: 18
  ident: BIB57
  article-title: A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms
  publication-title: Journal of Psychiatric Research
– volume: 47
  start-page: 8
  year: 2000
  end-page: 21
  ident: BIB20
  article-title: Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia
  publication-title: Biological Psychiatry
– volume: 50
  start-page: 871
  year: 1993
  end-page: 883
  ident: BIB50
  article-title: Continuity and discontinuity of affective disorders and schizophrenia: results of a controlled family study
  publication-title: Archives of General Psychiatry
– volume: 33
  start-page: 501
  year: 1990
  end-page: 505
  ident: BIB66
  article-title: Activities of blood glutathione peroxidase in schizophrenic and depressive patients
  publication-title: Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove
– year: 1994
  ident: BIB5
  publication-title: Diagnostic and Statistical Manual of Mental Disorders
– volume: 30
  start-page: 409
  year: 1991
  end-page: 412
  ident: BIB61
  article-title: Enzymes of the antioxidant defense system in chronic schizophrenic patients
  publication-title: Biological Psychiatry
– reference: Arvindakshan, M., 2003. Ph.D. Thesis: The Role of Membrane Essential Polyunsaturated Fatty Acids in Schizophrenia Outcome. Pune University Press, Pune, India
– volume: 26
  start-page: 995
  year: 2002
  end-page: 1005
  ident: BIB4
  article-title: The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the role of oxidant/antioxidant imbalance
  publication-title: Progress in Neuro-Psychopharmacology and Biological Psychiatry
– volume: 150
  start-page: 1405
  year: 1993
  end-page: 1407
  ident: BIB2
  article-title: Vitamin E treatment of tardive dyskinesia
  publication-title: American Journal of Psychiatry
– volume: 42
  start-page: 7
  year: 2000
  end-page: 17
  ident: BIB73
  article-title: Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients
  publication-title: Schizophrenia Research
– volume: 5
  start-page: 40
  year: 1987
  end-page: 48
  ident: BIB11
  article-title: Free radicals and the developmental pathophysiology of schizophrenic burnout
  publication-title: Integrative Psychiatry
– volume: 63
  start-page: 133
  year: 1996
  end-page: 142
  ident: BIB45
  article-title: Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal controls
  publication-title: Psychiatry Research
– volume: 8
  start-page: 151
  year: 1993
  end-page: 153
  ident: BIB59
  article-title: Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment
  publication-title: International Clinical Psychopharmacology
– volume: 32
  start-page: 805
  year: 1986
  end-page: 807
  ident: BIB1
  article-title: Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients
  publication-title: Clinical Chemistry
– volume: 15
  start-page: 287
  year: 2001
  end-page: 310
  ident: BIB74
  article-title: Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications
  publication-title: CNS Drugs
– volume: 24
  start-page: 357
  issue: 3
  year: 1997
  ident: 10.1016/S0165-1781(03)00220-8_BIB65
  article-title: Oxidative reactions and schizophrenia: a review-discussion
  publication-title: Schizophrenia Research
  doi: 10.1016/S0920-9964(97)00005-4
– ident: 10.1016/S0165-1781(03)00220-8_BIB29
– volume: 58
  start-page: 1
  year: 2002
  ident: 10.1016/S0165-1781(03)00220-8_BIB32
  article-title: Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics
  publication-title: Schizophrenia Research
  doi: 10.1016/S0920-9964(01)00334-6
– volume: 20
  start-page: 1
  year: 1991
  ident: 10.1016/S0165-1781(03)00220-8_BIB27
  article-title: Schizophrenia: manifestations, incidence and course in different cultures
  publication-title: Psychological Medicine and Monographs Supplement
  doi: 10.1017/S0264180100000904
– volume: 10
  start-page: 799
  year: 1962
  ident: 10.1016/S0165-1781(03)00220-8_BIB55
  article-title: Brief Psychiatric Rating Scale
  publication-title: Psychological Reports
  doi: 10.2466/pr0.1962.10.3.799
– volume: 150
  start-page: 1405
  year: 1993
  ident: 10.1016/S0165-1781(03)00220-8_BIB2
  article-title: Vitamin E treatment of tardive dyskinesia
  publication-title: American Journal of Psychiatry
  doi: 10.1176/ajp.150.9.1405
– volume: 33
  start-page: 501
  issue: 5
  year: 1990
  ident: 10.1016/S0165-1781(03)00220-8_BIB66
  article-title: Activities of blood glutathione peroxidase in schizophrenic and depressive patients
  publication-title: Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove
– volume: 56
  start-page: 407
  issue: 5
  year: 1999
  ident: 10.1016/S0165-1781(03)00220-8_BIB67
  article-title: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial
  publication-title: Archives of General Psychiatry
  doi: 10.1001/archpsyc.56.5.407
– volume: 95
  start-page: 351
  issue: 2
  year: 1979
  ident: 10.1016/S0165-1781(03)00220-8_BIB54
  article-title: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction
  publication-title: Analytical Biochemistry
  doi: 10.1016/0003-2697(79)90738-3
– volume: 45
  start-page: 742
  year: 1988
  ident: 10.1016/S0165-1781(03)00220-8_BIB71
  article-title: A structured interview guide for the Hamilton Depression Rating Scale
  publication-title: Archives of General Psychiatry
  doi: 10.1001/archpsyc.1988.01800320058007
– volume: 37
  start-page: 43
  year: 2002
  ident: 10.1016/S0165-1781(03)00220-8_BIB56
  article-title: Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain
  publication-title: Journal of Psychiatric Research
  doi: 10.1016/S0022-3956(02)00048-1
– volume: 40
  start-page: 1
  year: 1986
  ident: 10.1016/S0165-1781(03)00220-8_BIB26
  article-title: Schizophrenia and social adjustment. A prospective longitudinal study
  publication-title: Monogr Gesamtgeb Psychiatr Psychiatry Series
– volume: 36
  start-page: 7
  year: 2002
  ident: 10.1016/S0165-1781(03)00220-8_BIB57
  article-title: A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms
  publication-title: Journal of Psychiatric Research
  doi: 10.1016/S0022-3956(01)00048-6
– volume: 63
  start-page: 133
  issue: 2–3
  year: 1996
  ident: 10.1016/S0165-1781(03)00220-8_BIB45
  article-title: Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal controls
  publication-title: Psychiatry Research
  doi: 10.1016/0165-1781(96)02899-5
– volume: 32
  start-page: 805
  issue: 5
  year: 1986
  ident: 10.1016/S0165-1781(03)00220-8_BIB1
  article-title: Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients
  publication-title: Clinical Chemistry
  doi: 10.1093/clinchem/32.5.805
– volume: 85
  start-page: 275
  year: 1999
  ident: 10.1016/S0165-1781(03)00220-8_BIB39
  article-title: Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients
  publication-title: Psychiatric Research
  doi: 10.1016/S0165-1781(99)00014-1
– ident: 10.1016/S0165-1781(03)00220-8_BIB58
– volume: 5
  start-page: 40
  year: 1987
  ident: 10.1016/S0165-1781(03)00220-8_BIB11
  article-title: Free radicals and the developmental pathophysiology of schizophrenic burnout
  publication-title: Integrative Psychiatry
– volume: 149
  start-page: 22
  year: 1992
  ident: 10.1016/S0165-1781(03)00220-8_BIB69
  article-title: Are schizophrenia and affective disorder related? A selective literature review
  publication-title: American Journal of Psychiatry
  doi: 10.1176/ajp.149.1.22
– volume: 54
  start-page: 438
  issue: 3
  year: 1991
  ident: 10.1016/S0165-1781(03)00220-8_BIB64
  article-title: Omega-3 fatty acids in health and disease and in growth and development
  publication-title: American Journal of Clinical Nutrition
  doi: 10.1093/ajcn/54.3.438
– ident: 10.1016/S0165-1781(03)00220-8_BIB8
– volume: 16
  start-page: 193
  year: 1992
  ident: 10.1016/S0165-1781(03)00220-8_BIB70
  article-title: Do essential fatty acids play a role in brain and behavioral development?
  publication-title: Neuroscience and Biobehavioral Reviews
  doi: 10.1016/S0149-7634(05)80180-0
– volume: 159
  start-page: 477
  issue: 3
  year: 2002
  ident: 10.1016/S0165-1781(03)00220-8_BIB53
  article-title: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder
  publication-title: American Journal of Psychiatry
  doi: 10.1176/appi.ajp.159.3.477
– volume: 42
  start-page: 628
  issue: 3
  year: 1984
  ident: 10.1016/S0165-1781(03)00220-8_BIB63
  article-title: Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidation in the various regions of aging rat brain
  publication-title: Journal of Neurochemistry
  doi: 10.1111/j.1471-4159.1984.tb02728.x
– volume: 32
  start-page: 553
  year: 1996
  ident: 10.1016/S0165-1781(03)00220-8_BIB42
  article-title: Antioxidants in the treatment of schizophrenia
  publication-title: Drugs of Today
– ident: 10.1016/S0165-1781(03)00220-8_BIB34
– volume: 181
  start-page: 573
  issue: 2
  year: 1991
  ident: 10.1016/S0165-1781(03)00220-8_BIB68
  article-title: Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol
  publication-title: Biochemical and Biophysical Research Communications
  doi: 10.1016/0006-291X(91)91228-5
– volume: 22
  start-page: 131
  issue: 1
  year: 1992
  ident: 10.1016/S0165-1781(03)00220-8_BIB36
  article-title: The International Pilot Study of Schizophrenia: five-year follow-up findings
  publication-title: Psychological Medicine
  doi: 10.1017/S0033291700032797
– volume: 3
  start-page: 277
  year: 1984
  ident: 10.1016/S0165-1781(03)00220-8_BIB3
  article-title: Catalase in vitro
– volume: 11
  start-page: 471
  year: 1985
  ident: 10.1016/S0165-1781(03)00220-8_BIB15
  article-title: The two-syndrome concept: origins and current status
  publication-title: Schizophrenia Bulletin
  doi: 10.1093/schbul/11.3.471
– volume: 12
  start-page: 52
  issue: 1
  year: 1986
  ident: 10.1016/S0165-1781(03)00220-8_BIB25
  article-title: Epidemiology of schizophrenia: a European perspective
  publication-title: Schizophrenia Bulletin
  doi: 10.1093/schbul/12.1.52
– volume: 30
  start-page: 193
  issue: 3
  year: 1998
  ident: 10.1016/S0165-1781(03)00220-8_BIB24
  article-title: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia
  publication-title: Schizophrenia Research
  doi: 10.1016/S0920-9964(97)00151-5
– volume: 12
  start-page: 53
  year: 1994
  ident: 10.1016/S0165-1781(03)00220-8_BIB22
  article-title: A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases
  publication-title: Schizophrenia Research
  doi: 10.1016/0920-9964(94)90084-1
– volume: 30
  start-page: 409
  issue: 4
  year: 1991
  ident: 10.1016/S0165-1781(03)00220-8_BIB61
  article-title: Enzymes of the antioxidant defense system in chronic schizophrenic patients
  publication-title: Biological Psychiatry
  doi: 10.1016/0006-3223(91)90298-Z
– volume: 15
  start-page: 287
  issue: 4
  year: 2001
  ident: 10.1016/S0165-1781(03)00220-8_BIB74
  article-title: Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications
  publication-title: CNS Drugs
  doi: 10.2165/00023210-200115040-00004
– volume: 20
  start-page: 171
  issue: 2
  year: 2002
  ident: 10.1016/S0165-1781(03)00220-8_BIB35
  article-title: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder
  publication-title: Cell Biochemistry and Function
  doi: 10.1002/cbf.940
– volume: 26
  start-page: 995
  year: 2002
  ident: 10.1016/S0165-1781(03)00220-8_BIB4
  article-title: The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the role of oxidant/antioxidant imbalance
  publication-title: Progress in Neuro-Psychopharmacology and Biological Psychiatry
  doi: 10.1016/S0278-5846(02)00220-8
– volume: 42
  start-page: 7
  issue: 1
  year: 2000
  ident: 10.1016/S0165-1781(03)00220-8_BIB73
  article-title: Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients
  publication-title: Schizophrenia Research
  doi: 10.1016/S0920-9964(99)00095-X
– volume: 47
  start-page: 8
  year: 2000
  ident: 10.1016/S0165-1781(03)00220-8_BIB20
  article-title: Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia
  publication-title: Biological Psychiatry
  doi: 10.1016/S0006-3223(99)00092-X
– volume: 78
  start-page: 587
  year: 1988
  ident: 10.1016/S0165-1781(03)00220-8_BIB14
  article-title: Fat consumption and schizophrenia
  publication-title: Acta Psychiatrica Scandinavica
  doi: 10.1111/j.1600-0447.1988.tb06388.x
– volume: 53
  start-page: 56
  year: 2003
  ident: 10.1016/S0165-1781(03)00220-8_BIB10
  article-title: Membrane essential polyunsaturated fatty acids (EPUFA) and schizophrenia outcome: EPUFA and lipid peroxide levels in never-medicated and medicated schizophrenics
  publication-title: Biological Psychiatry
  doi: 10.1016/S0006-3223(02)01443-9
– volume: 62
  start-page: 195
  year: 2003
  ident: 10.1016/S0165-1781(03)00220-8_BIB9
  article-title: Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia
  publication-title: Schizophrenia Research
  doi: 10.1016/S0920-9964(02)00284-0
– volume: 55
  start-page: 65
  year: 1996
  ident: 10.1016/S0165-1781(03)00220-8_BIB46
  article-title: Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls
  publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids
  doi: 10.1016/S0952-3278(96)90147-7
– volume: 170
  start-page: 1
  year: 1995
  ident: 10.1016/S0165-1781(03)00220-8_BIB51
  article-title: The Nithsdale Schizophrenia Surveys XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia and in normal subjects
  publication-title: British Journal of Psychiatry
– volume: 39
  start-page: 789
  year: 1982
  ident: 10.1016/S0165-1781(03)00220-8_BIB6
  article-title: Negative vs. positive schizophrenia: definition and validation
  publication-title: Archives of General Psychiatry
  doi: 10.1001/archpsyc.1982.04290070025006
– volume: 13
  start-page: 195
  issue: 3
  year: 1994
  ident: 10.1016/S0165-1781(03)00220-8_BIB23
  article-title: The membrane hypothesis of schizophrenia
  publication-title: Schizophrenia Research
  doi: 10.1016/0920-9964(94)90043-4
– volume: 145
  start-page: 578
  year: 1988
  ident: 10.1016/S0165-1781(03)00220-8_BIB13
  article-title: Deficit and non-deficit forms of schizophrenia: the concept
  publication-title: American Journal of Psychiatry
  doi: 10.1176/ajp.145.5.578
– ident: 10.1016/S0165-1781(03)00220-8_BIB19
  doi: 10.1016/j.plefa.2003.08.010
– volume: 156
  start-page: 788
  year: 1990
  ident: 10.1016/S0165-1781(03)00220-8_BIB16
  article-title: The continuum of psychosis and its genetic origins: the sixty-fifth Maudsley Lecture
  publication-title: British Journal of Psychiatry
  doi: 10.1192/bjp.156.6.788
– volume: 33
  start-page: 5
  year: 1997
  ident: 10.1016/S0165-1781(03)00220-8_BIB40
  article-title: Essential fatty acids in the treatment of schizophrenia
  publication-title: Drugs of Today
– ident: 10.1016/S0165-1781(03)00220-8_BIB18
– volume: 19
  start-page: 19
  issue: 1
  year: 1996
  ident: 10.1016/S0165-1781(03)00220-8_BIB52
  article-title: Impaired antioxidant defense at the onset of psychosis
  publication-title: Schizophrenia Research
  doi: 10.1016/0920-9964(95)00048-8
– volume: 45
  start-page: 328
  year: 1988
  ident: 10.1016/S0165-1781(03)00220-8_BIB21
  article-title: A controlled family study of chronic psychosis
  publication-title: Archives of General Psychiatry
  doi: 10.1001/archpsyc.1988.01800280038006
– volume: 25
  start-page: 463
  issue: 3
  year: 2001
  ident: 10.1016/S0165-1781(03)00220-8_BIB41
  article-title: Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia
  publication-title: Progress in Neuropsychopharmacology and Biological Psychiatry
  doi: 10.1016/S0278-5846(00)00181-0
– volume: 49
  start-page: 359
  issue: 3
  year: 1995
  ident: 10.1016/S0165-1781(03)00220-8_BIB28
  article-title: Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs
  publication-title: Biochemical Pharmacology
  doi: 10.1016/0006-2952(94)00424-K
– volume: 55
  start-page: 27
  issue: 1–2
  year: 1996
  ident: 10.1016/S0165-1781(03)00220-8_BIB60
  article-title: Reduced susceptibility to oxidative damage of erythrocyte membranes from medicated schizophrenic patients
  publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids
  doi: 10.1016/S0952-3278(96)90142-8
– start-page: 99
  year: 1999
  ident: 10.1016/S0165-1781(03)00220-8_BIB49
  article-title: Membrane peroxidation and the neuropathology of schizophrenia
– volume: 158
  start-page: 1449
  year: 2001
  ident: 10.1016/S0165-1781(03)00220-8_BIB31
  article-title: Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database
  publication-title: American Journal of Psychiatry
  doi: 10.1176/appi.ajp.158.9.1449
– start-page: 151
  year: 1995
  ident: 10.1016/S0165-1781(03)00220-8_BIB17
  article-title: Psychotic continuum or disease entities? The critical impact of nosology on the problem of etiology
– volume: 32
  start-page: 385
  issue: 6
  year: 1998
  ident: 10.1016/S0165-1781(03)00220-8_BIB72
  article-title: Effects of haloperidol on antioxidant defense system enzymes in schizophrenia
  publication-title: Journal of Psychiatric Research
  doi: 10.1016/S0022-3956(98)00028-4
– start-page: 167
  year: 1999
  ident: 10.1016/S0165-1781(03)00220-8_BIB48
  article-title: Cultural and socio–economic differences in dietary intake of essential fatty acids and antioxidants: effects on the course and outcome of schizophrenia
– volume: 50
  start-page: 871
  year: 1993
  ident: 10.1016/S0165-1781(03)00220-8_BIB50
  article-title: Continuity and discontinuity of affective disorders and schizophrenia: results of a controlled family study
  publication-title: Archives of General Psychiatry
  doi: 10.1001/archpsyc.1993.01820230041004
– volume: 55
  start-page: 33
  issue: 1–2
  year: 1996
  ident: 10.1016/S0165-1781(03)00220-8_BIB62
  article-title: Free radical pathology in schizophrenia: a review
  publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids
  doi: 10.1016/S0952-3278(96)90143-X
– volume: 28
  start-page: 738
  issue: 8
  year: 1990
  ident: 10.1016/S0165-1781(03)00220-8_BIB12
  article-title: Chronic treatment with prolixin causes oxidative stress in rat brain
  publication-title: Biological Psychiatry
  doi: 10.1016/0006-3223(90)90461-A
– volume: 14
  start-page: 291
  year: 1988
  ident: 10.1016/S0165-1781(03)00220-8_BIB37
  article-title: Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms
  publication-title: Schizophrenia Bulletin
  doi: 10.1093/schbul/14.2.291
– volume: 19
  start-page: 1
  issue: 1
  year: 1996
  ident: 10.1016/S0165-1781(03)00220-8_BIB43
  article-title: Free radical pathology and antioxidant defense in schizophrenia: a review
  publication-title: Schizophrenia Research
  doi: 10.1016/0920-9964(95)00049-6
– volume: 57
  start-page: 5
  year: 2002
  ident: 10.1016/S0165-1781(03)00220-8_BIB7
  article-title: Historical aspects of the dichotomy between manic-depressive disorders and schizophrenia
  publication-title: Schizophrenia Research
  doi: 10.1016/S0920-9964(02)00328-6
– volume: 47
  start-page: 47
  year: 1993
  ident: 10.1016/S0165-1781(03)00220-8_BIB33
  article-title: Case identification and stability of the deficit syndrome of schizophrenia
  publication-title: Psychiatry Research
  doi: 10.1016/0165-1781(93)90054-K
– volume: 55
  start-page: 45
  year: 1996
  ident: 10.1016/S0165-1781(03)00220-8_BIB44
  article-title: Oxidative injury and potential use of antioxidants in schizophrenia
  publication-title: Prostaglandins, Leukotrienes and Essential Fatty Acids
  doi: 10.1016/S0952-3278(96)90144-1
– volume: 28
  start-page: 535
  year: 1990
  ident: 10.1016/S0165-1781(03)00220-8_BIB38
  article-title: Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia
  publication-title: Biological Psychiatry
  doi: 10.1016/0006-3223(90)90490-S
– year: 1994
  ident: 10.1016/S0165-1781(03)00220-8_BIB5
– volume: 43
  start-page: 674
  issue: 9
  year: 1998
  ident: 10.1016/S0165-1781(03)00220-8_BIB47
  article-title: Elevated plasma lipid peroxides at the onset of non-affective psychosis
  publication-title: Biological Psychiatry
  doi: 10.1016/S0006-3223(97)00282-5
– volume: 8
  start-page: 151
  issue: 3
  year: 1993
  ident: 10.1016/S0165-1781(03)00220-8_BIB59
  article-title: Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment
  publication-title: International Clinical Psychopharmacology
  doi: 10.1097/00004850-199300830-00003
– volume: 13
  start-page: 261
  issue: 2
  year: 1987
  ident: 10.1016/S0165-1781(03)00220-8_BIB30
  article-title: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
  publication-title: Schizophrenia Bulletin
  doi: 10.1093/schbul/13.2.261
SSID ssj0002199
Score 2.2714324
Snippet Oxidative stress-mediated cell damage has been considered in the pathophysiology of schizophrenia. Abnormal findings have often been considered related to...
SourceID proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 109
SubjectTerms Adult
Adult and adolescent clinical studies
Affect
Antioxidant enzymes
Antioxidants - metabolism
Apolipoproteins A - blood
Apolipoproteins B - blood
Biological and medical sciences
Bipolar Disorder - diagnosis
Bipolar Disorder - enzymology
Bipolar disorders
Bipolar mood disorder
Brief Psychiatric Rating Scale
Catalase - metabolism
Cell Membrane - metabolism
Cell Membrane - pathology
Cholesterol - blood
Erythrocytes - enzymology
Erythrocytes - pathology
Essential fatty acids
Fatty Acids, Essential - metabolism
Fatty Acids, Unsaturated - metabolism
Female
Glutathione Peroxidase - metabolism
Humans
Lipid peroxides
Male
Medical sciences
Mood disorders
Oxidative Stress - physiology
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychoses
Schizophrenia
Schizophrenia - diagnosis
Schizophrenia - enzymology
Schizophrenia - physiopathology
Severity of Illness Index
Superoxide Dismutase - metabolism
Triglycerides - blood
Wechsler Scales
Title Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0165178103002208
https://dx.doi.org/10.1016/S0165-1781(03)00220-8
https://www.ncbi.nlm.nih.gov/pubmed/14656446
https://www.proquest.com/docview/71429723
Volume 121
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Elsevier SD Complete Freedom Collection [SCCMFC]
  customDbUrl:
  eissn: 1872-7123
  dateEnd: 20191231
  omitProxy: true
  ssIdentifier: ssj0002199
  issn: 0165-1781
  databaseCode: ACRLP
  dateStart: 19950131
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection
  customDbUrl:
  eissn: 1872-7123
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002199
  issn: 0165-1781
  databaseCode: .~1
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals [SCFCJ]
  customDbUrl:
  eissn: 1872-7123
  dateEnd: 20191231
  omitProxy: true
  ssIdentifier: ssj0002199
  issn: 0165-1781
  databaseCode: AIKHN
  dateStart: 19950131
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1872-7123
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002199
  issn: 0165-1781
  databaseCode: AKRWK
  dateStart: 19790701
  isFulltext: true
  providerName: Library Specific Holdings
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Na9VAEB9KBRFE_PZVfe7Bgx7Sl2Q3Hz2Wankq7UULvS2b_YBAXxJMHvh68OQf7sxm09ceSsVTYNlZlpnJzG-ZL4D3QtM0JH0QaYoPipzbCEGsi9C5c5tUTjtLEd2T03x5Jr6eZ-c7cDTVwlBaZbD9o0331jqsLAI3F11dL75TIU5SlDQni8pFqeCXun-hTu__3qZ5pOMMSdoc0e5tFc94gl_8EPOP_pCovM0_PexUj1xz47iL2_Go90vHj-FRAJTscLzzE9ixzVO4fxJC5s_gzycPDHtrmKLMxl-1wS-zzeVmZXtcM2xlV_hmbiyjPuK4B4_r2ovNuump6yeCUcOcGoYNU7o2Pasb1l9L1dP-jKru6JHMVm1rmAktPVno2to_h7Pjzz-OllEYvRBpRGBD5KpUG5srdPBcxS4r4yqLE5WKokqdSkqqQM0FReWEQRtg8dGnDVlfxYXLsoy_gN2mbewrYLkpDVKmHuskrlJVUfC8SJw1yHF7MAMxMVzq0JecxmNcyGsJaHkmSU4y5tLLSZYz2L8i68bGHHcR5JM05VR1inZSouu4i7C8Iryhmv9COr-hNtubIspGbokZvJv0SOJ_TcEaFHe77mWRIFIoUj6Dl6N6bWmpxR1q-t7_3-s1PBiTEikt5w3sDj_X9i2Cq6Ga-79nDvcOv3xbnv4FZEgcXQ
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7SDbSFUvpKu22a6NBDe3DXD_mRY8iDTZPdSxPITch6gCFrm9oL3Z77wztjy7vJIST0ZBCeQYykmW-YF8AXrmgakjrwFMUHeRIZD0Gs9dC4RybIrbKGIrqzeTK94j-u4-stOBpqYSit0un-Xqd32tqtTJw0J3VRTH5SIU6QZjQni8pFsyewzWPUySPYPjw7n87XCjnsx0jS_x4RbAp5eibd4lc_-tbx8bL7TNSLWjYoONtPvLgfknam6fQVvHSYkh32234NW6Z8A09nLmr-Fv4ed9iwMZpJSm78XWj8MlP-WS1Mg2uaLcwC3ebSMGoljv8gu7q6WS3Lhhp_Ih7VzMq2XTGpCt2womTNrWw91fHIi5r8ZLaoKs206-rJXOPW5h1cnZ5cHk09N33BUwjCWs_modImkWjjI-nbOPPz2A9kyNM8tDLIqAg14RSY4xrVgEG_T2lSwDLiNo7jaAdGZVWaD8ASnWmkDDu4E9hc5mkaJWlgjUaJm4Mx8EHgQrnW5DQh40bcykFLYkHnJPxIdOcksjF8X5PVfW-OhwiS4TTFUHiKqlKg9XiIMFsT3rmdjyHdu3NtNjtFoI3S4mPYH-6RwKdN8Ro87mrZiDRAsJCG0Rje99drQ0td7tCR__j_-9qHZ9PL2YW4OJuff4LnfY4iZenswqj9tTSfEWu1-Z57S_8ADTsfCA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Decreased+antioxidant+enzymes+and+membrane+essential+polyunsaturated+fatty+acids+in+schizophrenic+and+bipolar+mood+disorder+patients&rft.jtitle=Psychiatry+research&rft.au=Ranjekar%2C+Prabhakar+K&rft.au=Hinge%2C+Ashwini&rft.au=Hegde%2C+Mahabaleshwar+V&rft.au=Ghate%2C+Madhav&rft.date=2003-12-01&rft.issn=0165-1781&rft.volume=121&rft.issue=2&rft.spage=109&rft.epage=122&rft_id=info:doi/10.1016%2FS0165-1781%2803%2900220-8&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_S0165_1781_03_00220_8
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0165-1781&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0165-1781&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0165-1781&client=summon